30
Participants
Start Date
April 10, 2019
Primary Completion Date
March 20, 2020
Study Completion Date
December 31, 2021
glecaprevir/pibrentasvir treatment
combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
Weill Cornell Medical Center, New York
University of Pennsylvania, Philadelphia
John Hopkins, Baltimore
University of Cincinnati Medical Center, Cincinnati
University of Michigan, Ann Arbor
Northwestern Medicine, Chicago
Massachusetts General Hospital, Boston
Collaborators (1)
AbbVie
INDUSTRY
University of Pennsylvania
OTHER
Johns Hopkins University
OTHER
University of Cincinnati
OTHER
Weill Medical College of Cornell University
OTHER
University of Michigan
OTHER
Northwestern University
OTHER
Raymond Chung
OTHER